BridgeBio Pharma BBIO Reportable Segment — Cost of Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's reportable segment — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's reportable segment — cost of revenue?
- BridgeBio Pharma (BBIO) reported reportable segment — cost of revenue of $9.94M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — cost of revenue changed year-over-year?
- BridgeBio Pharma's reportable segment — cost of revenue increased by 276.6% year-over-year, from $2.64M to $9.94M.
- What does reportable segment — cost of revenue mean?
- The direct costs incurred to produce and sell the goods or services of the segment.
- How do you interpret reportable segment — cost of revenue?
- An increase relative to revenue may signal margin compression or rising production costs.
- How does reportable segment — cost of revenue compare across companies?
- Standard cost of goods sold (COGS) metric found in all manufacturing and pharma firms.